Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada.

ABSTRACT:

Rationale & objective

The benefit-risk profile of rivaroxaban versus warfarin for atrial fibrillation (AF) in patients with chronic kidney disease is uncertain. We compared rivaroxaban with warfarin across the range of kidney function in adults with AF.

Study design

Multicenter retrospective cohort.

Setting & participants

Adults with AF and a measure of estimated glomerular filtration rate (eGFR); using administrative data from 5 jurisdictions across Australia and Canada (2011-2018). Kidney function was categorized as eGFR ≥60, 45-59, 30-44, and <30 mL/min/1.73 m². Patients receiving dialysis and kidney transplant recipients were excluded.

Exposures

New dispensation of either rivaroxaban or warfarin.

Outcomes

Composite (1) effectiveness outcom

SUBMITTER: Ha JT 

PROVIDER: S-EPMC10363562 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature